🚀 East China Pharmaceutical Subsidiary Receives FDA Approval for Clinical Trial
#EastChinaPharmaceutical #FDAApproval #ClinicalTrial #PhaseI #InjectableDrug #CancerTreatment #R&D #InternationalExpansion
East China Pharmaceutical announced that its wholly-owned subsidiary, Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd., has received approval from the U.S. Food and Drug Administration (FDA) to conduct a Phase I clinical trial in the United States. According to Jin10, the trial will focus on the injectable drug HDM2024, which is intended for the treatment of advanced solid tumors. This approval marks a significant step for the company in expanding its research and development efforts internationally.#EastChinaPharmaceutical #FDAApproval #ClinicalTrial #PhaseI #InjectableDrug #CancerTreatment #R&D #InternationalExpansion